ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Oral Bacteria Worsen Heart Attacks via B2 Cells 11/12/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded November 12, 2025. This episode summarizes 5 key cardiology studies on topics like proprotein convertase subtilisin/kexin 9 inhibitor and cardiovascular outcomes. Key takeaway: Oral Bacteria Worsen Heart Attacks via B2 Cells.
Article Links:
Article 1: Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank. (Journal of the American College of Cardiology)
Article 2: Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells. (Circulation)
Article 3: Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. (Circulation)
Article 4: High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. (Circulation)
Article 5: Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/oral-bacteria-worsen-heart-attacks-via-b2-cells-11-12-25/
Featured Articles
Article 1: Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41217319
Summary: The study aimed to evaluate if interleukin-6, a biomarker of inflammation, helps to further stratify atherosclerotic cardiovascular disease risk in individuals with elevated lipoprotein(a). Researchers utilized data from 6514 participants in the Multi-Ethnic Study of Atherosclerosis and 26574 participants from the U. K. Biobank. This research sought to identify if vascular inflammation, as indicated by interleukin-6 levels, provides additional insights into cardiovascular risk associated with high lipoprotein(a). Such findings could refine risk assessment and guide targeted preventative strategies for patients with elevated lipoprotein(a).
Article 2: Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40859845
Summary: This study investigated how oral pathobionts worsen myocardial infarction, addressing the unclear direct impact of periodontitis. Researchers utilized a mouse model combining ligature-induced periodontitis with myocardial infarction to assess this connection. They discovered that oral pathobionts accumulate ectopically in the heart and aggravate myocardial infarction through the mobilization of B2 cells. These findings elucidate a novel pathogenic mechanism linking periodontitis to myocardial infarction, highlighting the importance of oral health in cardiovascular disease.
Article 3: Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41212997
Summary: This phase two randomized, multicenter, double-blind, placebo-controlled trial investigated Coramitug, a humanized monoclonal antibody, for transthyretin amyloid cardiomyopathy. Unlike existing therapies that primarily slow progression, Coramitug is designed to target misfolded transthyretin and promote clearance of existing amyloid deposits through antibody-mediated phagocytosis. The study randomized participants with transthyretin amyloid cardiomyopathy to evaluate its safety and effectiveness. This research aims to establish a therapeutic agent that could significantly improve patient outcomes by actively removing pathogenic protein aggregates.
Article 4: High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41212981
Summary: Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. This prespecified pooled analysis, FLUNITY-HD, aimed to clarify the effectiveness of high-dose inactivated influenza vaccine against specific cardiovascular outcomes in older adults. The study integrated data from two harmonized, individually randomized trials. While the high-dose vaccine has demonstrated superior protection against various hospitalization endpoints, its specific impact on cardiovascular events and in patients with existing cardiovascular disease needed further elucidation. This research sought to provide crucial evidence to guide influenza vaccination strategies for cardiovascular protection in this vulnerable population.
Article 5: Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41212178
Summary: The CAVIAR Trial, an investigator-initiated, prospective, multicenter, double-blind, randomized study, investigated alirocumab for cardiac allograft vasculopathy inhibition. The study aimed to establish the safety and effectiveness of proprotein convertase subtilisin/kexin 9 inhibition to lower cholesterol and prevent cardiac allograft vasculopathy early after heart transplantation. Participants were randomized to receive either alirocumab or a placebo. If successful, this intervention could significantly reduce mortality associated with cardiac allograft vasculopathy and improve long-term outcomes for heart transplant recipients.
Transcript
Today’s date is November 12, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank. The study aimed to evaluate if interleukin-6, a biomarker of inflammation, helps to further stratify atherosclerotic cardiovascular disease risk in individuals with elevated lipoprotein(a). Researchers utilized data from 6514 participants in the Multi-Ethnic Study of Atherosclerosis and 26574 participants from the U. K. Biobank. This research sought to identify if vascular inflammation, as indicated by interleukin-6 levels, provides additional insights into cardiovascular risk associated with high lipoprotein(a). Such findings could refine risk assessment and guide targeted preventative strategies for patients with elevated lipoprotein(a).
Article number two. Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells. This study investigated how oral pathobionts worsen myocardial infarction, addressing the unclear direct impact of periodontitis. Researchers utilized a mouse model combining ligature-induced periodontitis with myocardial infarction to assess this connection. They discovered that oral pathobionts accumulate ectopically in the heart and aggravate myocardial infarction through the mobilization of B2 cells. These findings elucidate a novel pathogenic mechanism linking periodontitis to myocardial infarction, highlighting the importance of oral health in cardiovascular disease.
Article number three. Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. This phase two randomized, multicenter, double-blind, placebo-controlled trial investigated Coramitug, a humanized monoclonal antibody, for transthyretin amyloid cardiomyopathy. Unlike existing therapies that primarily slow progression, Coramitug is designed to target misfolded transthyretin and promote clearance of existing amyloid deposits through antibody-mediated phagocytosis. The study randomized participants with transthyretin amyloid cardiomyopathy to evaluate its safety and effectiveness. This research aims to establish a therapeutic agent that could significantly improve patient outcomes by actively removing pathogenic protein aggregates.
Article number four. High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. This prespecified pooled analysis, FLUNITY-HD, aimed to clarify the effectiveness of high-dose inactivated influenza vaccine against specific cardiovascular outcomes in older adults. The study integrated data from two harmonized, individually randomized trials. While the high-dose vaccine has demonstrated superior protection against various hospitalization endpoints, its specific impact on cardiovascular events and in patients with existing cardiovascular disease needed further elucidation. This research sought to provide crucial evidence to guide influenza vaccination strategies for cardiovascular protection in this vulnerable population.
Article number five. Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial. The CAVIAR Trial, an investigator-initiated, prospective, multicenter, double-blind, randomized study, investigated alirocumab for cardiac allograft vasculopathy inhibition. The study aimed to establish the safety and effectiveness of proprotein convertase subtilisin/kexin 9 inhibition to lower cholesterol and prevent cardiac allograft vasculopathy early after heart transplantation. Participants were randomized to receive either alirocumab or a placebo. If successful, this intervention could significantly reduce mortality associated with cardiac allograft vasculopathy and improve long-term outcomes for heart transplant recipients.
Thank you for listening. Don’t forget to subscribe.
Keywords
proprotein convertase subtilisin/kexin 9 inhibitor, cardiovascular outcomes, influenza vaccine, oral pathobionts, Coramitug, B2 cells, high-dose influenza vaccine, lipoprotein(a), FLUNITY-HD, phase two trial, cardiac allograft vasculopathy, MESA, older adults, alirocumab, inflammation, atherosclerotic cardiovascular disease, periodontitis, interleukin-6, heart transplantation, risk stratification, CAVIAR trial, transthyretin amyloid cardiomyopathy, monoclonal antibody, amyloid clearance, myocardial infarction.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Oral Bacteria Worsen Heart Attacks via B2 Cells 11/12/25 first appeared on Cardiology Today.
Article Links:
Article 1: Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank. (Journal of the American College of Cardiology)
Article 2: Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells. (Circulation)
Article 3: Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. (Circulation)
Article 4: High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. (Circulation)
Article 5: Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/oral-bacteria-worsen-heart-attacks-via-b2-cells-11-12-25/
Featured Articles
Article 1: Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41217319
Summary: The study aimed to evaluate if interleukin-6, a biomarker of inflammation, helps to further stratify atherosclerotic cardiovascular disease risk in individuals with elevated lipoprotein(a). Researchers utilized data from 6514 participants in the Multi-Ethnic Study of Atherosclerosis and 26574 participants from the U. K. Biobank. This research sought to identify if vascular inflammation, as indicated by interleukin-6 levels, provides additional insights into cardiovascular risk associated with high lipoprotein(a). Such findings could refine risk assessment and guide targeted preventative strategies for patients with elevated lipoprotein(a).
Article 2: Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40859845
Summary: This study investigated how oral pathobionts worsen myocardial infarction, addressing the unclear direct impact of periodontitis. Researchers utilized a mouse model combining ligature-induced periodontitis with myocardial infarction to assess this connection. They discovered that oral pathobionts accumulate ectopically in the heart and aggravate myocardial infarction through the mobilization of B2 cells. These findings elucidate a novel pathogenic mechanism linking periodontitis to myocardial infarction, highlighting the importance of oral health in cardiovascular disease.
Article 3: Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41212997
Summary: This phase two randomized, multicenter, double-blind, placebo-controlled trial investigated Coramitug, a humanized monoclonal antibody, for transthyretin amyloid cardiomyopathy. Unlike existing therapies that primarily slow progression, Coramitug is designed to target misfolded transthyretin and promote clearance of existing amyloid deposits through antibody-mediated phagocytosis. The study randomized participants with transthyretin amyloid cardiomyopathy to evaluate its safety and effectiveness. This research aims to establish a therapeutic agent that could significantly improve patient outcomes by actively removing pathogenic protein aggregates.
Article 4: High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41212981
Summary: Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. This prespecified pooled analysis, FLUNITY-HD, aimed to clarify the effectiveness of high-dose inactivated influenza vaccine against specific cardiovascular outcomes in older adults. The study integrated data from two harmonized, individually randomized trials. While the high-dose vaccine has demonstrated superior protection against various hospitalization endpoints, its specific impact on cardiovascular events and in patients with existing cardiovascular disease needed further elucidation. This research sought to provide crucial evidence to guide influenza vaccination strategies for cardiovascular protection in this vulnerable population.
Article 5: Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41212178
Summary: The CAVIAR Trial, an investigator-initiated, prospective, multicenter, double-blind, randomized study, investigated alirocumab for cardiac allograft vasculopathy inhibition. The study aimed to establish the safety and effectiveness of proprotein convertase subtilisin/kexin 9 inhibition to lower cholesterol and prevent cardiac allograft vasculopathy early after heart transplantation. Participants were randomized to receive either alirocumab or a placebo. If successful, this intervention could significantly reduce mortality associated with cardiac allograft vasculopathy and improve long-term outcomes for heart transplant recipients.
Transcript
Today’s date is November 12, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk: MESA and UK Biobank. The study aimed to evaluate if interleukin-6, a biomarker of inflammation, helps to further stratify atherosclerotic cardiovascular disease risk in individuals with elevated lipoprotein(a). Researchers utilized data from 6514 participants in the Multi-Ethnic Study of Atherosclerosis and 26574 participants from the U. K. Biobank. This research sought to identify if vascular inflammation, as indicated by interleukin-6 levels, provides additional insights into cardiovascular risk associated with high lipoprotein(a). Such findings could refine risk assessment and guide targeted preventative strategies for patients with elevated lipoprotein(a).
Article number two. Oral Pathobionts Aggravate Myocardial Infarction Through Mobilization of B2 Cells. This study investigated how oral pathobionts worsen myocardial infarction, addressing the unclear direct impact of periodontitis. Researchers utilized a mouse model combining ligature-induced periodontitis with myocardial infarction to assess this connection. They discovered that oral pathobionts accumulate ectopically in the heart and aggravate myocardial infarction through the mobilization of B2 cells. These findings elucidate a novel pathogenic mechanism linking periodontitis to myocardial infarction, highlighting the importance of oral health in cardiovascular disease.
Article number three. Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. This phase two randomized, multicenter, double-blind, placebo-controlled trial investigated Coramitug, a humanized monoclonal antibody, for transthyretin amyloid cardiomyopathy. Unlike existing therapies that primarily slow progression, Coramitug is designed to target misfolded transthyretin and promote clearance of existing amyloid deposits through antibody-mediated phagocytosis. The study randomized participants with transthyretin amyloid cardiomyopathy to evaluate its safety and effectiveness. This research aims to establish a therapeutic agent that could significantly improve patient outcomes by actively removing pathogenic protein aggregates.
Article number four. High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. This prespecified pooled analysis, FLUNITY-HD, aimed to clarify the effectiveness of high-dose inactivated influenza vaccine against specific cardiovascular outcomes in older adults. The study integrated data from two harmonized, individually randomized trials. While the high-dose vaccine has demonstrated superior protection against various hospitalization endpoints, its specific impact on cardiovascular events and in patients with existing cardiovascular disease needed further elucidation. This research sought to provide crucial evidence to guide influenza vaccination strategies for cardiovascular protection in this vulnerable population.
Article number five. Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial. The CAVIAR Trial, an investigator-initiated, prospective, multicenter, double-blind, randomized study, investigated alirocumab for cardiac allograft vasculopathy inhibition. The study aimed to establish the safety and effectiveness of proprotein convertase subtilisin/kexin 9 inhibition to lower cholesterol and prevent cardiac allograft vasculopathy early after heart transplantation. Participants were randomized to receive either alirocumab or a placebo. If successful, this intervention could significantly reduce mortality associated with cardiac allograft vasculopathy and improve long-term outcomes for heart transplant recipients.
Thank you for listening. Don’t forget to subscribe.
Keywords
proprotein convertase subtilisin/kexin 9 inhibitor, cardiovascular outcomes, influenza vaccine, oral pathobionts, Coramitug, B2 cells, high-dose influenza vaccine, lipoprotein(a), FLUNITY-HD, phase two trial, cardiac allograft vasculopathy, MESA, older adults, alirocumab, inflammation, atherosclerotic cardiovascular disease, periodontitis, interleukin-6, heart transplantation, risk stratification, CAVIAR trial, transthyretin amyloid cardiomyopathy, monoclonal antibody, amyloid clearance, myocardial infarction.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Oral Bacteria Worsen Heart Attacks via B2 Cells 11/12/25 first appeared on Cardiology Today.
More episodes of the podcast Cardiology Today
CRISPR-Cas9 Gene Editing for Lipids 11/11/25
11/11/2025
In God we trust